Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma

D Schadendorf; E Richtig; C Loquai; A Forschner; R Gutzmer; S Haferkamp; J Utikal; JC Hassel; F Meier; Dirk Debus; M Fluck; D Goeppner; H Kehrer; R Dummer; R von Moos; J Thompson; L Gengenbacher; O Michielin; C Hoeller

Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma

D Schadendorf, E Richtig, C Loquai, A Forschner, R Gutzmer, S Haferkamp, J Utikal, JC Hassel, F Meier, Dirk Debus, M Fluck, D Goeppner, H Kehrer, R Dummer, R von Moos, J Thompson, L Gengenbacher, O Michielin, C Hoeller

Universitätsklinik für Dermatologie

Publikation: Beitrag in Fachzeitschrift › publizierter Abstrakt (Zeitschrift) › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	236-236
Fachzeitschrift	Oncology Research and Treatment
Jahrgang	45
Ausgabenummer	SUPPL 3
Publikationsstatus	Veröffentlicht - 2022

Dieses zitieren

Schadendorf, D., Richtig, E., Loquai, C., Forschner, A., Gutzmer, R., Haferkamp, S., Utikal, J., Hassel, JC., Meier, F., Debus, D., Fluck, M., Goeppner, D., Kehrer, H., Dummer, R., von Moos, R., Thompson, J., Gengenbacher, L., Michielin, O., & Hoeller, C. (2022). Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma. Oncology Research and Treatment, 45(SUPPL 3), 236-236.

@article{bc2cd4734f9b4638a095edd81894d1ec,

title = "Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma",

author = "D Schadendorf and E Richtig and C Loquai and A Forschner and R Gutzmer and S Haferkamp and J Utikal and JC Hassel and F Meier and Dirk Debus and M Fluck and D Goeppner and H Kehrer and R Dummer and {von Moos}, R and J Thompson and L Gengenbacher and O Michielin and C Hoeller",

year = "2022",

language = "English",

volume = "45",

pages = "236--236",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

number = "SUPPL 3",

}

Schadendorf, D, Richtig, E, Loquai, C, Forschner, A, Gutzmer, R, Haferkamp, S, Utikal, J, Hassel, JC, Meier, F, Debus, D, Fluck, M, Goeppner, D, Kehrer, H, Dummer, R, von Moos, R, Thompson, J, Gengenbacher, L, Michielin, O & Hoeller, C 2022, 'Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma', Oncology Research and Treatment, Jg. 45, Nr. SUPPL 3, S. 236-236.

Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma. / Schadendorf, D; Richtig, E; Loquai, C et al.
in: Oncology Research and Treatment, Jahrgang 45, Nr. SUPPL 3, 2022, S. 236-236.

Publikation: Beitrag in Fachzeitschrift › publizierter Abstrakt (Zeitschrift) › Begutachtung

TY - JOUR

T1 - Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma

AU - Schadendorf, D

AU - Richtig, E

AU - Loquai, C

AU - Forschner, A

AU - Gutzmer, R

AU - Haferkamp, S

AU - Utikal, J

AU - Hassel, JC

AU - Meier, F

AU - Debus, Dirk

AU - Fluck, M

AU - Goeppner, D

AU - Kehrer, H

AU - Dummer, R

AU - von Moos, R

AU - Thompson, J

AU - Gengenbacher, L

AU - Michielin, O

AU - Hoeller, C

PY - 2022

Y1 - 2022

M3 - published Abstract (Journal)

SN - 2296-5270

VL - 45

SP - 236

EP - 236

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

IS - SUPPL 3

ER -